MAPK3 and ovarian cancer: [12], [13], [14], [15] Drugs targeting different molecular components involved in protein synthesis machinery are already in clinical trials for various tumor types including breast, colon, and colorectal cancers [16], [17], [18], supporting the translational potential of our hits. Network characterization using IPA software showed that the genes in the network with the highest score exhibited their downstream effects through, ERK1/2 and AKT, key survival genes which have been implicated as mediators of major oncogenic pathways in ovarian cancer (Figure S3C) [19], [20], [21], [22].